** Shares of drug developer Halozyme Therapeutics HALO.O gain ~13% to $51.5 premarket
** Co withdraws offer to buy German drug developer Evotec EVTG.DE for 11 euro per share, or 2 billion euros ($2.09 billion)
** U.S.-listed shares of Evotec EVO.O down about 17% at $4.43 before the bell
** HALO CEO Helen Torley says EVO "has been unwilling to engage with us to explore a potential combination and a company spokesperson has publicly commented that its goal is to remain an independent company"
** Adds that multiple requests to meet with the chairwoman of EVO's supervisory board were not accepted
** HALO announced its proposal to buy EVO on Nov 14
** As of last close, HALO up ~24% YTD and EVO down ~53% YTD
($1 = 0.9589 euros)
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。